Oncimmune Holdings plc appoints new Scientific Board
Dr Adam Hill, CEO of Oncimmune commented: “Oncimmune’s forward strategy is designed to unlock the latent potential in the Company’s immunogenic protein platform, through developing a number of commercial propositions,